<DOC>
	<DOCNO>NCT00082914</DOCNO>
	<brief_summary>RATIONALE : Denileukin diftitox may able make body build immune response kill tumor cell . PURPOSE : This phase II trial study well denileukin diftitox work treat patient metastatic melanoma metastatic kidney cancer .</brief_summary>
	<brief_title>Denileukin Diftitox Treating Patients With Metastatic Melanoma Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine clinical response patient metastatic melanoma metastatic kidney cancer treat denileukin diftitox . Secondary - Determine whether change occur level CD4-positive CD25-positive lymphocyte peripheral blood patient treatment drug . - Determine toxicity profile drug patient . OUTLINE : Patients stratify accord disease type ( metastatic melanoma v metastatic kidney cancer ) . Patients receive denileukin diftitox IV 1 hour day 1-5 , 21-25 , 42-46 , 63-67 . Treatment repeat every 84 day ( 12 week ) maximum total 5 course absence disease progression , autoimmune ocular toxicity attributable denileukin diftitox , unacceptable toxicity . At time therapy , patient achieve complete response receive 1 additional course therapy complete response . PROJECTED ACCRUAL : A total 10-96 patient ( 5-48 per stratum ) accrue study within 3-4 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Melanoma Kidney cancer Metastatic disease Measurable disease Documented disease progression receive standard therapy No resectable local regional disease PATIENT CHARACTERISTICS : Age 16 Performance status ECOG 02 Life expectancy More 3 month Hematopoietic WBC ≥ 3,000/mm^3 Platelet count ≥ 90,000/mm^3 Lymphocyte count ≥ 500/mm^3 No concurrent coagulation disorder Hepatic Bilirubin ≤ 2.0 mg/dL ( &lt; 3.0 mg/dL patient Gilbert 's syndrome ) AST ALT &lt; 3 time normal Albumin ≥ 2.5 g/dL Hepatitis B surface antigen negative Hepatitis C antibody negative Renal Creatinine ≤ 2.0 mg/dL Cardiovascular Normal thallium stress test* No prior myocardial infarction No history severe coronary artery disease No major medical illness cardiovascular system NOTE : *For patient &gt; 50 year age OR history cardiovascular disease Pulmonary No major medical illness respiratory system Immunologic HIV negative No active systemic infection No presence opportunistic infection No primary secondary immunodeficiency No autoimmune disease No know immunodeficiency Other No sensitivity denileukin diftitox component ( e.g. , diphtheria toxin , interleukin2 , excipients ) Willing undergo leukapheresis Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Prior treatment interleukin2 allow provided patient 's disease status require therapy Chemotherapy Recovered prior chemotherapy Endocrine therapy No concurrent systemic steroid Radiotherapy Recovered prior radiotherapy Surgery Not specify Other More 3 week since prior systemic anticancer therapy No concurrent systemic anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>